Gilead Rebuffs Dems' Sovaldi Request; Waxman Doesn't Expect House To Act

Sovaldi-maker Gilead hasn't complied with a request from House Democrats to justify the $84,000-per-course treatment of the hepatitis C drug, Energy & Commerce Ranking Democrat Henry Waxman (CA) said Wednesday, but a Gilead official said the company is complying with a similar request for information from the Senate Finance Committee. Waxman, who spearheaded the House request, said Congress is “highly unlikely” to pass drug-price controls anytime soon, and a health care analyst said industry made that same assessment months ago...